Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04561102 · ClinicalTrials.gov registry record
Evaluation of the COVIDSeq Test in Nasal Swab and Saliva From a COVID-19 Asymptomatic Population
A clinical trial, sponsored by Illumina.
- Completed
- Registry status
- 644
- Enrollment target
NCT04561102: Completed study, sponsored by Illumina.
NCT04561102 is a clinical trial that has completed, run by Illumina. The registered enrollment target is 644 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04561102 has completed, sponsored by Illumina.
- COMPLETED
- Registry status
- 644 participants
- Enrollment target
Study Summary
"This is a prospective, single-center specimen collection study. Subjects 18 years of age or older who do not have symptoms of COVID-19 will be enrolled. Two nasal swab samples and one saliva sample will be collected from each subject. The saliva sample will be tested with the COVIDSeq Test and one nasal swab will be tested with an EUA approved COVID test. The other nasal swab sample will be stored and a subset (approximately 250 specimens) will be tested with the COVIDSeq Test. Results of all testing will be provided to the sponsor for statistical analysis. Results from the comparator EUA test will be provided to the collection site investigator or designated collection site study staff. No medical treatment, guidance on treatment decisions, nor medical care will be provided. "
Interventions
- DIAGNOSTIC_TEST Diagnostic test for detection of SARS-CoV-2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 644 participants |
| Start Date | 2020-09-11 |
| Est. Completion | 2021-02-28 |
What the finished NCT04561102 record still lists
NCT04561102 is an observational study that tracks outcomes without assigning an intervention. The registered 644 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Diagnostic test for detection of SARS-CoV-2 is the first listed.
NCT04561102 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04561102 about?
NCT04561102 is a clinical study titled "Evaluation of the COVIDSeq Test in Nasal Swab and Saliva From a COVID-19 Asymptomatic Population". "This is a prospective, single-center specimen collection study. Subjects 18 years of age or older who do not have symptoms of COVID-19 will be enrolled. Two nasal swab samples and one saliva sample will be collected from each subject. The saliva sample will be tested with the COVIDSeq Test and one ...
What is the current status of trial NCT04561102?
This trial is currently completed. The enrollment target is 644 participants. The study started on 2020-09-11. Estimated completion is 2021-02-28.
What interventions are being tested in trial NCT04561102?
The interventions under investigation include: Diagnostic test for detection of SARS-CoV-2 (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04561102?
This trial is sponsored by Illumina, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05146297 · 644 participants · NA
Diversity and Inclusion in Research Underpinning Prevention and Therapy Trials
- NCT06994442 · 644 participants · Phase 3
Optimizing Pain Treatment in Children On Mechanical Ventilation
- NCT07012395 · 645 participants · Phase 2
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
- NCT04863222 · 646 participants · Phase 4
Clinical and Radiographic Success of MTA vs Biodentine
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI